Titan Biotech announces 1:5 stock split with February 20, 2026 record date

Titan Biotech Limited has confirmed a stock split that changes the structure of its equity shares. The company has fixed Friday, February 20, 2026 as the record date for this corporate action. Shareholders whose names appear in the register on that date will qualify for the revised share entitlement after the split.

Under this decision, each existing equity share with a face value of Rs 10 will be split. Investors will receive five fully paid-up equity shares, each carrying a face value of Rs 2, for every current share. This move adjusts the number of units held but keeps the economic ownership unchanged.

"We wish to inform you that pursuant to Regulation 42 of the Listing Regulations, the Company has fixed Friday, February 20, 2026, as the Record Date for the purpose of determining the eligibility of Members for the sub-division / Split of 1 (one) equity share of face value of Rs. 10/- (Rupees Ten) each, fully paid-up, into 5 (five) equity shares of face value of Rs. 2/- (Rupees Two) each, fully paid-up as approved by the Members of the Company through Postal Ballot on December 30, 2025." said Titan Biotech in a regulatory filing.

The company stated that the decision had already received shareholder consent through a postal ballot on December 30, 2025. By reducing the face value from Rs 10 to Rs 2, Titan Biotech aims to widen participation. The objective is to make the share price more accessible while preserving each investor’s percentage holding in the company.

The stock split leads to a sizeable change in Titan Biotech’s capital structure, while total capital stays constant. The number of authorised, issued, and paid-up shares rises sharply, but each carries a lower face value. This structural change is a standard approach for companies planning to improve liquidity in their listed equity.

Before the stock split, Titan Biotech’s authorised share capital consisted of 1,00,00,000 equity shares. Each share carried a face value of Rs 10. After the subdivision, the authorised capital is represented by 5,00,00,000 equity shares, with the face value reduced to Rs 2 for every share.

Issued, subscribed, and paid-up capital figures have also been adjusted to reflect the 1:5 split ratio. Issued equity shares increased from 82,63,700 units with a face value of Rs 10. Following the split, this stands at 4,13,18,500 equity shares, each having a face value of Rs 2, matching the subscribed and paid-up capital.

Particulars	Before Titan Biotech stock split	After Titan Biotech stock split
Face value per equity share	Rs 10	Rs 2
Authorised equity shares	1,00,00,000	5,00,00,000
Issued equity shares	82,63,700	4,13,18,500
Subscribed and paid-up equity shares	82,63,700	4,13,18,500

Titan Biotech stock split impact on investors and liquidity

The split ratio for Titan Biotech is 1:5, meaning every existing share converts into five new shares. Investors appearing as shareholders before the record date on February 20, 2026 will receive these additional units automatically. No separate action or application is required from eligible shareholders for receiving the split shares.

While the number of shares grows fivefold, the total market value of each holding remains unchanged. The market adjusts the quoted share price after the split, usually dividing the pre-split price by five. For example, an investor holding 100 shares before February 20 would hold 500 shares after the adjustment.

Stock splits are often used to support trading activity and improve market liquidity, especially where prices have risen. Lower per-share prices may attract a broader base of retail investors. Analysts and market watchers therefore monitor such actions closely for any change in volumes or investor interest following the effective date.

Titan Biotech stock split and technical outlook

Alongside the corporate action, some analysts have highlighted short-term technical signals on Titan Biotech’s share price. The views relate to recent chart patterns and potential levels that traders may track. These comments focus on support and resistance zones rather than company fundamentals.

"Titan Biotech stock price is bearish with strong resistance at 1154 on the Daily charts. A Daily close below support of 1020 could lead to a target of 857 in the near term," commented A R Ramachandran, part-time SEBI-registered Research Analyst, Tips2trades.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred to as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.

The Titan Biotech stock split keeps overall capital intact while raising the number of tradable shares. Record date eligibility is fixed for February 20, 2026, and the 1:5 ratio shapes all post-split holdings. For investors, the key effects relate to liquidity, affordability per share, and the technical view that some analysts continue to track.